|
| | EMpagliflozin iMpurity 14 Basic information |
| Product Name: | EMpagliflozin iMpurity 14 | | Synonyms: | (2S,3R,4R,5S,6R)-2-(4-chloro-3-(hydroxy(4-(((S)-tetrahydrofuran-
3-yl)oxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-
pyran-3,4,5-triol;Empagliflozin Impurity 64;Empagliflozin-13;Empagliflozin impurity 16/(2S,3R,4R,5S,6R)-2-(4-chloro-3-(hydroxy(4-(((S)-tetrahydrofuran- 3-yl)oxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H- pyran-3,4,5-triol;D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[hydroxy[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)- | | CAS: | 2137418-13-2 | | MF: | C23H27ClO8 | | MW: | 466.91 | | EINECS: | | | Product Categories: | | | Mol File: | 2137418-13-2.mol |  |
| | EMpagliflozin iMpurity 14 Chemical Properties |
| Boiling point | 706.3±60.0 °C(Predicted) | | density | 1.456±0.06 g/cm3(Predicted) | | pka | 13.18±0.20(Predicted) |
| | EMpagliflozin iMpurity 14 Usage And Synthesis |
| Uses | Hydroxy Empagliflozin is an impurity of Empagliflozin (E521510), a novel, potent and selective SGLT-2 inhibitor. It improves glycaemic control syndrome in diabetic rats. |
| | EMpagliflozin iMpurity 14 Preparation Products And Raw materials |
|